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Abstract
Background: Since 1990 non communicable diseases and injuries account for the majority of death and disability-adjusted
life years in Latin America. We analyzed the relationship between the global burden of disease and Randomized Clinical
Trials (RCTs) conducted in Latin America that were published in the five leading medical journals.
Methodology/Principal Findings: We included all RCTs in humans, exclusively conducted in Latin American countries, and
published in any of the following journals: Annals of Internal Medicine, British Medical Journal, Journal of the American
Medical Association, Lancet, and New England Journal of Medicine. We described the trials and reported the number of RCTs
according to the main categories of the global burden of disease. Sixty-six RCTs were identified. Communicable diseases
accounted for 38 (57%) reports. Maternal, perinatal, and nutritional conditions accounted for 19 (29%) trials. Non-
communicable diseases represent 48% of the global burden of disease but only 14% of reported trials. No trial addressed
injuries despite its 18% contribution to the burden of disease in 2000.
Conclusions/Significance: A poor correlation between the burden of disease and RCTs publications was found. Non
communicable diseases and injuries account for up to two thirds of the burden of disease in Latin America but these topics
are seldom addressed in published RCTs in the selected sample of journals. Funding bodies of health research and editors
should be aware of the increasing burden of non communicable diseases and injuries occurring in Latin America to ensure
that this growing epidemic is not neglected in the research agenda and not affected by publication bias.
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Introduction
It has been estimated that less than 10% of health research
spending is directed toward diseases or conditions that account for
90% of the global burden of disease, a phenomenon referred to as
the ‘‘10/90 gap’’.[1] The gap is also reflected in the low
proportion of publications arising from research in low and
middle income countries, where most of the global burden of
disease occurs.[2]
Addressing context specific research questions are fundamental
to designing interventions that improve health. Randomized
controlled trials (RCTs) are the gold standard to assess the
effectiveness of interventions. An unbiased design and adequate
reporting of RCTs that specifically address diseases which affect
low and middle income countries can have an impact in changing
medical practice and influencing public health policy.
Five of the world’s leading medical journals—Annals of Internal
Medicine, British Medical Journal (BMJ), Journal of the American
Medical Association (JAMA), Lancet, and New England Journal of
Medicine (NEJM)—have together the highest impact in medical
research, and therefore, they can have a large influence on clinical
medicine and public health worldwide. In relation to this group of
medical journals, one of its editors stated that ‘‘Their international
success brings global responsibilities to the communities they serve
and profit from...’’ and that they should raise ‘‘the priority of
papers from less-developed countries in line with global burdens of
disease’’.[3] Unfortunately, there is good evidence of the under
representation of research addressing common conditions from
developing countries in these leading journals.[2,4,5,6]
Bibliometric analyses—a set of methods used to study or
measure texts and information—have been done to illustrate the
gaps of the published medical literature, either in terms of subjects
covered, representation of journal’s editorial boards, and specif-
ically, the under-representation of low and middle income
countries in high-impact general medical journals.[6,7,8,9]
Latin-American and Caribbean countries have experienced a
rapid epidemiological transition and since 1990 non communica-
ble diseases and injuries already account for the majority of death
and disability-adjusted life years in the region.[10,11] No previous
studies have investigated the relationship between RCTs and the
burden of disease in Latin America. Description of this
relationship can provide information about gaps between the
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information can contribute to the establishment of a research
agenda and prioritize neglected conditions.
We analyzed the relationship between the global burden of
disease and RCTs conducted in Latin America published in five
leading medical journals.
Methods
Eligibility Criteria
We included all RCT s in humans, exclusively conducted in
Latin American countries (by this we mean that the population
was located in Latin America irrespective of the origin of the
researcher) and published in any of the following journals: Annals of
Internal Medicine, BMJ, JAMA, Lancet and NEJM. The definition
used for RCTs was an experiment in which investigators randomly
allocate eligible participants into an intervention group (arm) each
of which receives one or more of the interventions (or none) that
are being compared.[12]
Identification of the trials
We searched the PubMed database registers from 1990 up to
December 2006 using the Cochrane Sensitive Search Strategy, which is
highly sensitivity to identify RCTs, and combined it with the terms
‘‘Latin America’’ or ‘‘Latin America’’ and all the country names
from the region.[13] We limited the search strategy to the five
selected medical journals (Annals of Internal Medicine, BMJ, JAMA,
Lancet and NEJM). (See Appendix S1 for the full search strategy).
Data extraction
From selected trials, the following data were extracted: name of
the first author, year of publication, country(ies) where the study
was conducted, number of participants, description of disease
evaluated according to groups of global burden of disease and type
of funding. Data extraction and data entry was made indepen-
dently by two reviewers. Differences in data extraction were
resolved by a third party.
Data analysis
We conducted a descriptive analysis listing the number of
RCTs, participants and countries in which the studies were
conducted. We also reported the number of RCTs according to
the main categories of the global burden of disease.
Results
Of 181 reports initially obtained, 66 (36%) fulfilled the inclusion
criteria and were retrieved for the analysis.
Table 1 displays the general characteristics of the reports
included. The majority of the trials were published in Lancet and
the countries with the highest numbers of publications were Brazil
and Mexico. Cluster trials accounted for one-fifth of all the
publications. We found no defined trend in the frequency of
publications during this time. Most of the trials were non-
commercial.
Communicable diseases accounted for 38 (57%) reports.
Maternal, perinatal, and nutritional conditions accounted for 19
(29%) trials, and 9 (14%) addressed non-communicable diseases.
Within the latter group, 4 trials evaluated cardiovascular disease, 1
cancer and 4 other non-communicable diseases. We found no
RCTs assessing interventions for injuries. The most common
individual condition evaluated was traveler’s diarrhea, which was
studied in 4 (6%) of the trials. (See table 2 for the full details of
reports included).
We found an overall poor correlation between the global
burden of disease and the topic of the published RCTs conducted
in Latin America. The mismatch is evident in the following figures:
non-communicable diseases represent 48% of the burden of
disease and 14% of the RCTs; no RCTs addressed injuries despite
these representing 18% of the burden of disease in 2000 (see
Figure 1).
Discussion
There is an evident mismatch between the burden of disease in
and publications from Latin America. Non communicable diseases
and injuries account for up to two thirds of the burden of disease in
Latin America but these topics are seldom addressed in published
Table 1. General Characteristics of the reports included
Publications per journal n (%)
Lancet 30 (46)
BMJ 12 (18)
NEJM 12(18)
JAMA 6 (9)
Annals 6 (9)
Publications per country* n
Brazil 14
Mexico 12
Argentina 9
Chile 6
Venezuela 5
Haiti 5
Peru 5
Colombia 4
Unit of randomization n (%)
Individuals 54 (81)
Clusters 12 (19)
Date of publication n (%)
1990–1992 10 (15)
1993–1995 14 (22)
1996–1998 10 (15)
1999–2001 8 (12)
2002–2004 12 (18)
2005–2006 12 (18)
Type of funding n(%)
Non commercial 42 (64)
Commercial 6 (9)
Both 12 (18)
Not reported 6(9)
Sample Size mean (range)
Patients included per report 275 (26 to 348,139)
Conditions according to the Global
Burden of Disease Study
n( % )
Communicable diseases 38 (57)
Maternal perinatal and nutritional 19 (29)
Non-Communicable diseases 9 (14)
doi:10.1371/journal.pone.0001696.t001
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Year Journal Participants Cluster Funding Specific Condition
Global Burden of
Disease Classification Countries
1990 Lancet 81621 no Non-commercial Salmonela Tiphy Communicable Chile
1990 Jama 227 no Non-commercial traveller’s diahrrea Communicable Mexico
1991 NEJM 101 no Commercial Infant meningitis Communicable Costa Rica
1991 NEJM 1194 no Non-commercial Hipertensive disorders
in pregnancy
Maternal, perinatal
and nutrition
Argentina
1991 NEJM 86 no Commercial Infant diarrea Maternal, perinatal
and nutrition
Costa Rica
1992 NEJM 2235 no Non-commercial Delivery and low birth weight Maternal, perinatal
and nutrition
Argentina, Brasil, Cuba,
and Mexico
1992 Jama 191 no Both traveller’s diahrrea Communicable Mexico
1992 NEJM 110 no Not reported Leshmaniasis Communicable Colombia
1992 Lancet 29113 no Non-commercial Lepra Communicable Venezuela
1992 Jama 278 no Commercial DTP vaccine response Communicable Chile
1993 Lancet 2606 no Non-commercial Delivery, episiotomy Maternal, perinatal
and nutrition
Argentina
1993 Annals 126 no Commercial Artritis reumatoidea NCD Mexico
1993 Lancet 11124 si Both Diarrhea and respiratory
infections in infants
Communicable Haiti
1993 Lancet 118 no Non-commercial HiV and Tuberculosis Communicable Haiti
1993 NEJM 275 no Both Diarrea Communicable Peru
1993 Lancet 1548 no Non-commercial Malaria Communicable Colombia
1993 Lancet 159 no Non-commercial Infant diarrea Communicable Guatemala and Brazil
1993 Lancet 4534 no Commercial Acute Miocardial Infarction NCD Argentina, Brasil, Chile,
Paraguay, Uruguay and
Venezuela
1994 Lancet 88 no Non-commercial traveller’s diahrrea Communicable Belize
1994 Lancet 1563 no Not reported Colera Communicable Peru
1994 Lancet 275 no Non-commercial Kangaroo low birth
weight infants
Maternal, perinatal
and nutrition
Ecuador
1994 Lancet 516 no Not reported Heart Failure NCD Argentina
1994 Lancet 141 no Non-commercial Infant nutrition Maternal, perinatal
and nutrition
Honduras
1994 Lancet 1240 no Non-commercial Diarrea e infecciones
respitatorias pediatricas
Maternal, perinatal
and nutrition
Brasil
1996 Lancet 130 no Non-commercial Chagas Communicable Brasil
1997 NEJM 2207 no Both Rotavirus Diarrrea Communicable Venezuela
1997 BMJ 472 no Non-commercial Childhood Pneumonia Communicable Brasil
1997 Lancet 113 no Non-commercial Filariasis in childrem Communicable Haiti
1997 Annals 187 no Not reported Leshmaniasis Communicable Colombia
1997 Lancet 202 no Both Coronary Heart Disease NCD Argentina
1997 BMJ 591 no Non-commercial Blood pressure of children Maternal, perinatal
and nutrition
Argentina
1998 Annals 176 no Non-commercial Malaria Communicable Colombia
1998 Lancet 627 no Non-commercial Haemofilus in infants Communicable Chile
1998 NEJM 53 no Not reported Acute Respiratory Syndrome Communicable Brasil
1999 BMJ 101 no Both Snake bite Communicable Brasil
1999 Jama 543 no Non-commercial Meningitis Communicable Chile
1999 Lancet 130 no Non-commercial Breastfeeding Maternal, perinatal
and nutrition
Mexico
2000 Lancet 233 no Non-commercial Tuberculosis Communicable Haiti
2000 Lancet 12926 no Non-commercial HIV Communicable Nicaragua
2000 Annals 42 no Non-commercial HIV Communicable Haiti
2000 NEJM 135 no Commercial Infant diarrea Communicable Peru
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were retrieved evaluated infectious diseases, and within this group,
the predominant condition studied was traveler’s diarrhea, a
condition that may be more relevant to travelers from developed
countries visiting less developed areas. Previous studies have
reported the paucity of RCTs addressing the diseases of low and
middle income countries.[5,14,15] However, to the best of our
knowledge previous studies have not explored the relation between
global burden of disease and RCTs in Latin America.
The gap identified in our study may have different explanations
including lack of original research that mirror the burden of
disease or a higher rate of RCTs publications addressing
communicable, maternal, perinatal and nutritional conditions.
The latter could be due to better quality of the design and
reporting of the original studies. Alternatively editors and
reviewers from the leading journals could be biased to include
publications from Latin America when they focus on these
conditions.
Why is important to conduct RCTs in Latin America?
As previously stated, context is crucial to decide which
interventions are effective in specific populations because the
effect—and therefore the impact—of some interventions could
differ according to the setting. This is of particular relevance for
those interventions that address behavioral modifications or
involve health services.[16] Preventive interventions in injuries
targeting behaviors that could be strongly influenced by cultural
conditions or the adherence to medication in chronic conditions
like cardiovascular diseases are some of the situations where RCTs
are needed. A good example of this type of research is the DIAL
Trial which addressed the case management of patients with
chronic heart failure.[17] Furthermore, for chronic diseases the
relevant outcome of interest is quality of life, so local evidence is
necessary since this type of ‘‘soft’’ outcome is more culturally
dependent. Another important reason to conduct trials in the
region is that certain diseases predominantly occur in Latin
America, such as Chagas disease[18] or Hemorrhagic Argentine
Year Journal Participants Cluster Funding Specific Condition
Global Burden of
Disease Classification Countries
2001 Jama 1193 no Both Respiratory tract infection
in infants
Communicable Dominicana
2002 BMJ 2913 si Both Leshmaniasis Communicable Venezuela
2002 Lancet 26 no Non-commercial Altitude polycythaemia NCD Bolivia
2003 BMJ 301 no Non-commercial Agitation in mental health Maternal, perinatal and
nutrition
Brasil
2003 Lancet 240 no Non-commercial Depression Maternal, perinatal and
nutrition
Chile
2004 Lancet 70 clusters si Non-commercial Infant and maternal health Maternal, perinatal and
nutrition
Honduras
2004 BMJ 210 si Non-commercial Snake bite Communicable Ecuador
2004 BMJ 139 si Non-commercial Infant malnutrition Maternal, perinatal and
nutrition
Jamaica
2004 Lancet 149276 si Non-commercial Delivery Maternal, perinatal and
nutrition
Argentina, Brasil, Cuba,
Guatemala and Mexico
2004 Jama 795 si Non-commercial Infant anaemia and nutrition Maternal, perinatal and
nutrition
Mexico
2004 BMJ 120 no Non-commercial Tetanus Communicable Brasil
2004 NEJM 68 no Not reported Cardia arrest NCD Brasil
2004 NEJM 120 no Both Neurocisticercosys Communicable Peru
2005 Lancet 348139 si Non-commercial Tuberculosis Communicable Brasil
2005 Lancet 350 no Non-commercial Breastfeeding Maternal, perinatal and
nutrition
Brasil
2005 BMJ 1518 no Non-commercial Heart Failure NCD Argentina
2005 Lancet 277 si Non-commercial Infan nutrition Maternal, perinatal and
nutrition
Peru
2005 Annals 210 no Both traveller’s diahrrea Communicable Mexico
2005 NEJM 162 no Both Lupus NCD Mexico
2006 BMJ 232 no Non-commercial Depression Maternal, perinatal and
nutrition
Jamaica
2006 Lancet 476 no Non-commercial Infant anaemia Maternal, perinatal and
nutrition
Mexico
2006 BMJ 10049 si Both Dengue Communicable Venezuela
2006 Lancet 2373 si Non-commercial Parasites Communicable Ecuador
2006 BMJ 10954 si Non-commercial HIV Communicable Mexico
2006 Annals 30 no Non-commercial Glioblastoma NCD Mexico
doi:10.1371/journal.pone.0001696.t002
Table 2. cont.
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population and scientific community.
Why is important to publish the results of the RCTs?
A fundamental step after study completion is to publish the
findings in scientific journals. The publication in the five leading
medical journals, in particular, can influence clinical practice and
policy.[19] These journals are particularly relevant in low and
middle income where limited resources require that medical
libraries subscribe to only a few international journals, and
therefore, prioritize those with the higher impact. The publication
of RCTs conducted on the region will not only disseminate the
results appropriately but will also raise the awareness of the topic
and potentially could help to increase the funding for research in
these conditions.
Limitations
A limitation of our study is that we only considered five leading
medical journals. We acknowledge that many of the trials
conducted in Latin America may have been published in different
journals, however we considered that those published on the
leading journals will have the larger visibility and impact amongst
the medical and health care community.
Another important limitation is that we included RCTs
exclusively conducted in Latin America and, therefore, we
excluded international trials which may have enrolled participants
from this region. Most of the international trials are sponsored by
the pharmaceutical industry, which may answer important
questions but are less likely to influence the public health of low
and middle income countries in the short term.[20] Nonetheless,
the Latin America region has also seen good examples of
international trials that study generic drugs for prevalent diseases
or conditions with direct relevance to the region. For example,
Latin America has had an active participation in the MRC
CRASH Trial,[21] which evaluated the effect of corticosteroids on
head injury, or the CREATE-ECLA trial,[22] which evaluated the
effect of the glucose-insulin-potassium (GIK) infusion in patients
with myocardial infarction. Another good example is the Magpie
trial, which assessed the effects of magnesium sulphate in
approximately 10,000 women with pre-eclampsia, including
women from Latin America, and resulted in a change of clinical
practice.[23] Conducting regional RCTs will also promote the
development of skills and infrastructure which will allow Latin
America’s researchers to participate in international collaborations
addressing these generic but locally relevant questions.
Finally, a further limitation of this report is that we only
included RCTs, and it is possible that observational studies carried
out in topics such as non communicable diseases and injuries are
less likely to be published in the five leading medical journals
which may favor RCTs.
What are the future challenges?
In this paper we only focused on published reports, yet it is
widely recognized that only a small proportion of studies reach the
publication stage. Unfortunately, at the moment, there is not any
source with complete information about RCTs conducted
available in Latin America. The World Health Organization is
actively promoting an international initiative to develop registers
of controlled trials.[24] In Latin America, the Colombian Branch
of The Iberoamerican Cochrane Network developed the Latin
American Ongoing Clinical Trials Register (LATINREC) which,
when fully active, will represent a unique opportunity to obtain a
detailed profile of the research conducted in the region.[25] The
analysis of this register will confirm or not the gap found in this
report and it will enable researchers and policy makers to draw an
appropriate research profile of the region. It will be possible to
identify duplication of work, inequitable funding of research,
neglected diseases and other aspect such as source of funding and
quality of design and reporting of clinical trials.[26]
In addition, editorial boards should not only avoid ‘‘bias against
the diseases of poverty’’ but, in the context of the epidemiological
transition occurring in developing regions, such as Latin America,
Figure 1. Relation between Global Burden of Disease and RCTs in LAC published in the five leading medical journals. The figure
shows an evident mismatch: non-communicable diseases represented 48% of the burden of disease in LAC and 14% of the RCTs. No RCTs addressed
injuries despite these representing 18% of the DALYs in 2000.
doi:10.1371/journal.pone.0001696.g001
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poverty. This predisposition could partially explain why while
Latin America experienced an increase of non-communicable
diseases and injuries in the last 20 years, this epidemic was not
mirrored by the RCTs published in the five leading medical
journals.
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